Novartis announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta treatment for up to six years in recently diagnosed treatment-naive people living with relapsing
Novartis announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta treatment for up to six years in recently diagnosed treatment-naive people living with relapsing
Novartis (NVS) presented results from a pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study of Fabhalta, an investigational Factor B inhibitor of the alternative complement pathway, in patients with
The Management Board and Supervisory Board of MorphoSys AG (MOR) issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary
The Management Board and Supervisory Board of MorphoSys (MOR) issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of
Arvinas (ARVN) announced it has entered into an exclusive strategic license agreement with Novartis (NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC androgen receptor degrader